NRD
VERA icon

Nebula Research & Development’s Vera Therapeutics VERA Stock Holding History

Nebula Research & Development’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-19,634
Closed -$463K – 842
2025
Q2 		$463K Buy
+19,634
New +$441K 0.04% 654

Other funds holding VERA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nebula Research & Development's VERA Position: Q3 2025 in Review

Nebula Research & Development sold out of Vera Therapeutics (VERA) in Q3 2025, closing a stake of 19,634 shares — an estimated $463K sold.

Nebula Research & Development first reported a position in VERA in Q2 2025 and held it in 1 quarter. The position peaked at $463K in Q2 2025. 175 funds tracked by Wall St. Rank hold VERA as of Q3 2025.

  • Nebula Research & Development reported no remaining Vera Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Nebula Research & Development sold 19,634 Vera Therapeutics shares in Q3 2025, an estimated $463K.
  • Nebula Research & Development first reported a position in Vera Therapeutics in Q2 2025 and held it in 1 quarter.
  • Nebula Research & Development's Vera Therapeutics position peaked at $463K in Q2 2025.
  • 175 funds tracked by Wall St. Rank held Vera Therapeutics as of Q3 2025.

Based on Nebula Research & Development's 13F filing for Q3 2025.